We are a clinical-stage pharmaceutical company focused on developing, manufacturing and commercializing novel, locally administered therapies using our transformational PLEX (Polymer-Lipid Encapsulation matriX) technology. The Company’s product pipeline candidates are designed to address unmet medical needs by pairing PLEX technology with approved pharmaceuticals which are delivered locally at predetermined release rates and durations over periods ranging from days to several months. PLEX technology has the potential to improve patient outcomes and lower the overall cost of treatment by enabling customizable, controlled local delivery of drugs, thereby addressing many of the shortcomings of systemic administration and existing localized delivery systems. PLEX technology may represent a paradigm shift in the treatment of several localized medical conditions, including infection, pain, inflammation and cancer.
The PLEX™ (Polymer-Lipid Encapsulation matriX) platform is a matrix made of alternating layers of polymers and lipids that entrap a therapeutic drug between them in order to form a protected reservoir that enables an effective localized drug delivery at the target site.
PLEX-based drug reservoirs enable prolonged delivery of unmodified drugs over periods ranging from days to several months. The application of our PLEX™ technology enables to optimize drug treatment regimens by predetermining release rates and durations, a rare combination of attributes.
The PLEX™ platform is able to accommodate a large variety of different molecules, regardless of size or physical characteristics:
We invite companies to partner with us by utilizing our PLEX™ platform as a local drug delivery vehicle that will optimize their drugs’ therapeutic effect and clinical outcome. We offer fast and easy partnering process: